James Kimball Rigged Conviction

The actual accounting of exactly how this conspiratorial group came together, along with the actual communication between the groups when they were setting up their second illegal raid (search and seizure ) of Kimball and his companies on May 12, 1993. The actual faxed communications were acquired from Dana Barnett (President of Somerset Pharmaceuticals and Vice President of Mylan Pharmaceuticals) when Mr. Barnett inadvertently provided Kimball's attorney at the time, with the wrong documents.

These communications were authenticated in court by the private detective agency's owner; Sean McWeeney, owner of Corporate Risk in Virginia . Sean McWeeney verified that the communications were between he and Dana Barnett and that he perjured himself when he testified against Kimball.

Note: When Kimball requested these documents be admitted into evidence for perjury, and to be compiled with a multitude of other evidence of violations of law and Kimball's constitutional rights; corrupt Judge Lazzara refused to admit any of the documents or other evidence Kimball had.

Viewing Documents 11-15 of 40

The Conspiracy (Pt. 3)

The pages in this web site section contain exhibit summaries and exhibits of original documents and each are numbered consecutively. Most every page, or exhibit summary, with few exceptions are divided into parts. Part one is a summary explanation of what the document or documents at the end of the page depicts.

Resolved: Government and Pharmaceutical Companies conspire to put DEDI (the company) out of Business and Mr. Kimball in jail.

DOCUMENT #11

The manufacturing and formulations were varied for C.A.S., the name changed to Liquid Deprenyl Citrate (LDC) and LDC was imported legally into the United States under FDA exemption policy and to other countries for humanitarian purposes.

DOCUMENT #12

Submissions were filed by DEDI and Mr. Kimball with the FDA to request the FDA'S advisory opinion that LDC was a drug for use in Alzheimer's disease and quality of life. Click to review documents.

Below are links to view acutal sanned in correspondence from the FDA to Mr. Kimball regarding the submissions by Mr. Kimball for Liquid Deprenyl Citrate to be deemed a drug

Exhibit Thirteen-1 - Actual FDA Document Correspondence pg. 1

Exhibit Thirteen-2 - Actual FDA Document Correspondence pg. 2

Exhibit Thirteen-3 - Actual FDA Document Correspondence pg. 3

DOCUMENT #13

THE CONSPIRACY THICKENS......READ CAST OF COSPIRATORS AND THE CAST OF VICTIMS

The conspiracy thickens as Somerset Pharmaceuticals, the FDA, the U.S. Justice Department, U.S. Customs, the Florida Department of Law Enforcement, Florida Department of Health (DOH), and others all unite to be rid of DEDI and Mr. Kimball. Somerset Pharmaceuticals hires Corporate Risk International, a high profile international detective agency headed by Sean McWeeney, an ex-FBI department head, to infiltrate the government and state investigations of DEDI and Mr. Kimball; to unite them with Somerset in a team effort to put DEDI out of business and Mr. Kimball in jail. In a fax letter dated October, 1992 from Mr. McWeeney to Dana Barnett, President and CEO of Somerset Pharmaceuticals, it’s clear Mr. McWeeney was welcomed with open arms and united with government officials and gaining information.

Dana Barnett was also the Vice-President of Mylan Pharmaceuticals. In this letter, Mr. McWeeney tells Mr. Barnett he is getting investigational material and information from Phil Halpern in San Diego, an Assistant U.S. Prosecuting Attorney for the Justice Department. Mr. Halpern advises Mr. McWeeney of the agencies helping him and the charges he is seeking against DEDI and Mr. Kimball. In the end, Mr. Halpern tells Mr. McWeeney that he is available to give him future updates and asks for assistance from Somerset. Mr. McWeeney also notes correspondence with Don Leggett who is Compliance Safety Officer in the Office of Compliance at the Food and Drug Administration, Rockville, MD.

CAST OF CONSPIRATORS PERTAINING TO EXHIBIT DOCUMENTS 14 - 28

Tara Arcamono - A supervisory employee of Somerset Pharmaceuticals

Dana Barnett - President and CEO of Somerset, Vice-President of Mylan Pharmaceuticals

Sheila Biehl - An attorney for Somerset with the firm of Gunster, Yoakley in Stewart, Florida

Kevin Black - A private investigator for Somerset's attorneys Gunster, Yoakley in Stewart, Florida

Bristol Myers-Squibb - Pharmaceutical manufacturing company

Allan Carroll - An FBI Investigator

Mr. Chesmore - The Associate Commissioner of the FDA in Rockville, Maryland

Jose Cordova - A Supervisor for U.S. Customs in Tampa, Florida

Corporate Risk International - A world wide high profile private investigation firm hired by Somerset

Dennis Degan - A Supervisor at FDA headquarters in Rockville, Maryland

Brian Dunne - Investigator for Bristol Myers-Squibb

Eli-Lilly - A large pharmaceutical manufacturing and distributing company

Philip Halpern - Assistant U.S. Prosecuting Attorney in San Diego, California

Buzz Howell - The Director of Security for Eli-Lilly

Gregg Jones - Agent Supervisor of the Florida Department of Health

Dave Kiessling - FDA Investigator

Don Leggett - a Compliance Officer at FDA headquarters in Rockville, Maryland

Nan Mantell - In-house attorney and on the Board of Directors of Somerset Pharmaceuticals

Sean McWeeney - an ex-FBI Supervisor currently President of Corporate Risk International, see Exhibit Document 16-2-3

Cris Meade - an Assistant U.S. Attorney in Maryland

John Moser - Prosecutor for the Florida Office of Statewide Prosecution

Debra Orr - admitted Federal Agent, member of Federal task force since 1992. Employee of the Florida Department of Health.

Steve Page - Somerset's Florida attorney of Gunster, Yoakley, Valdez-Fauli, and Stuart in Stewart, Florida

Steve Perez - a Special Agent Supervisor for U.S. Customs, San Diego, California

Sandoz - A large pharmaceutical manufacturer and distributor, exclusively distributes Somerset's Eldepryl product

Sinofi - A foreign pharmaceutical company that sells a deprenyl hydrochloride product containing selegiline hydrochloride

Phillip Smith - Field Investigator for the FDA, former FBI agent working and employed by Bristol Myers-Squibb

Somerset - Somerset Pharmaceuticals owned by Mylan and Bolar Pharmaceuticals

CAST OF VICTIMS OF GOVERNMENT CONSPIRACY PERTAINING TO DOCUMENTS 14-28

Apoter - An alleged foreign distributer of pharmaceuticals that were coming into the U.S. in concert with Interpharm

Bill Faloon - the President of Life Extension Foundation in Florida and an advocate of freedom of choice in medicine

Interpharm - A pharmaceutical producer and distributor from the Bahamas

Fountain Research - a company that distributes supplement and nutrient products

Saul Kent - A Director for the Life Extension Foundation in Florida and an advocate of freedom of choice in medicine

James T. Kimball - President of Discovery Experimental and Development, Inc. (DEDI) a pharmaceutical research facility, ASTAK, Inc. a dietary supplement research company, and Global Health Information and Medical Research Institute a non-profit organization of doctors and scientists providing free information to the public

Toni Kimball - James T. Kimball's daughter

Life Extension Foundation - A company which provides information for consumers about serious health concerns that are not readily available through other sources. They also provide information about acquiring products that may not be readily available in the U.S. but are overseas. Some of the products they provide information on can improve quality of life, longevity, and in some instances, save lives.

B. Mougios - a pharmaceutical company in Greece that manufactures and distributes pharmaceuticals world wide

Mr. Schectman - a key person with Interpharm

Mr. Sherman - a key person with Interpharm

Kerwin Whitnah - the founder of Fountain Research

The allegations set forth in the following documents by Somerset's investigators and government agents were untrue and no charges were ever filed on such allegations against Mr. Kimball or DEDI by U.S. attorney Phil Halpern.

Exhibit Fourteen-1 - View communications between U.S. government agents and pharamceutical companies and their agents.

Exhibit Fourteen-2 - View communications between U.S. government agents and pharamceutical companies and their agents.

DOCUMENT #14

F.D.A, F.B.I., BRISTOL-MYERS & SOMERSET CONSPIRACY

On November 2, 1992, Mr. McWeeney faxes a letter to Mr. Barnett about another conversation with Mr. Halpern. In this letter McWeeney references a discussion with Nan Mantell, Somerset’s in-house counsel who is on the Board of Directors of Somerset. Mr. Halpern tells Mr. McWeeney criminal actions against DEDI and Mr. Kimball are upcoming and for Somerset not to take any “overt actions” in the next few weeks. “Overt actions” was incorrect terminology, clandestine is the proper word for what Somerset was doing in their investigation of Mr. Kimball and DEDI, and Mr. Halpern knew it.

Mr. Halpern tells Somerset not to file their civil action against DEDI and Mr. Kimball. Mr. McWeeney goes on to tell Mr. Barnett about another conspiracy with government agents with the FDA and FBI involving Bristol-Myers and Somerset; out to close another company called Interpharm for legally importing a deprenyl product and other products from outside the U.S., purportedly the Bahamas. Discussed is the fact that FDA Agent Phillip Smith is working for Bristol-Myers to set up Interpharm with an FBI Agent Alan Carroll and to wire tap conversations. Nothing like the FDA being in bed with the pharmaceutical companies. Click to view letter.

EXHIBIT Fifteen1-1 - View communications between U.S. Government Agents and pharmaceutical companies and their agents

EXHIBIT Fifteen1-2 - View communications between U.S. Government Agents and pharmaceutical companies and their agents

DOCUMENT #15

F.B.I. MEETING WITH RESULTS GIVEN TO TWO PARMACEUTICAL COMPANIES

EXHIBIT Sixteen 1 - View communications between U.S. Government Agents and pharmaceutical companies and their agents

EXHIBIT Sixteen 2-1 - View communications between U.S. Government Agents and pharmaceutical companies and their agents

EXHIBIT Sixteen 2-2 - View communications between U.S. Government Agents and pharmaceutical companies and their agents

< Previous Page

View Next Page >

1-5 | 6-10 | 11-15 | 16-20 | >